MUNICH, Germany – Merck, a leading global science and technology company, today announced the successful launch of a state-of-the-art high-performance computer (HPC) located in Munich. This significant upgrade to Merck’s digital infrastructure is designed to dramatically accelerate research and innovation across its three primary business sectors: Healthcare, Life Science, and Electronics.
The initiative underscores Merck’s strategic commitment to embedding digital capabilities throughout its operations, utilizing advanced computing as a primary enabler of scientific discovery. The new HPC platform is expected to significantly reduce time and costs associated with research, allowing scientists to conduct more experiments and bring innovations to market faster.
At Merck, speed and efficiency translate directly into patient and customer benefit,
Our new high-performance computer enhances our research by significantly reducing time and cost. This enables our scientists across all our sectors to conduct more experiments, accelerate development and deliver innovative treatments to patients and advanced technologies to customers – faster and more effectively.
Laura Matz
Read More: Merck Group Q3 2025: Strong Organic Growth Across All Sectors
A Strategic Partnership for Hybrid Innovation
The supercomputer is the result of a strategic collaboration between Merck, Lenovo Group Ltd., and Equinix Inc.
The infrastructure is configured with Lenovo’s powerful ThinkSystem servers. Crucially, to address the massive heat generated by high-performance computing, the system integrates Lenovo’s industry-leading Neptune™ liquid cooling technology. This ensures that even the most demanding computational workloads run efficiently.
The HPC platform is located within an “AI-ready” data center in Munich operated by Equinix. The design features a hybrid cloud infrastructure, combining private and public cloud resources. This architecture offers the flexibility to scale rapidly to meet varying computational demands, particularly those required for managing complex artificial intelligence (AI) and machine learning (ML) models.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Accelerating Progress Across Three Sectors
By unifying high-performance computing under one roof, Merck aims to minimize fragmentation and foster collaboration between its diverse research teams. The HPC will be deployed to tackle unique challenges in each sector:
- Healthcare: Streamlining and accelerating complex drug discovery processes to bring new treatments to patients sooner.
- Life Science: Enhancing product development cycles for research and biomanufacturing tools.
- Electronics: Optimizing the development of cutting-edge new materials vital for the semiconductor industry.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
